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Abstract
Left Ventricular Assist Device (LVAD) therapy use is increasing rapidly in
advanced heart failure (HF). Little data exists on the application of this therapy in
patients with advanced HF due to hypertrophic cardiomyopathy (HCM). Altered
ventricular geometry, thickened septum and reduced LV end-diastolic diameter
(LVEDD) in HCM may lead to increased suction events, arrhythmias and inflow
cannula malfunction.
We hypothesized that patients with end stage HCM benefit from LVAD therapy
and have a similar rate of complications to those with ischemic or dilated CM.
Between 2009 and 2014, 5 patients with end stage HCM (HCM and EF <50%),
were implanted with either a HeartMate II ® (80%) or HVAD® (20%) device, as a
bridge-to-transplant (BTT) (80%) or destination therapy (DT) (20%). We compared
baseline characteristics, surgical, and long-term clinical outcomes between these
patients and those receiving an LVAD for end stage dilated and ischemic CM
(n=214) during that time frame. The HCM cohort had a smaller LVEDD (5.2 versus
6.9 cm, p=0.001) and a higher LVEF (28% v 18%, p=0.002).
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Cardiopulmonary bypass time was similar between the groups (72min vs 69min).
Post-operative length of stay was also similar at 21 days. Operative mortality for
HCM patients was 0. All 4 BTT patients survived to transplant. LVAD therapy
resulted in improved LVEDD (5.2 cm to 3.9 cm), PASP (58.8 mmHg to 30.8
mmHg), and cardiac index (1.5 to 2.82L/min/m2) in patients with HCM, without an
increased incidence of postoperative complications. Median duration of LVAD
support in the HCM group was 14 months and 10 months for the control.
We conclude that select patients with end stage HCM may benefit from LVAD
therapy with a similar rate of complications compared to traditional candidates.
Additional study is warranted to further evaluate durable mechanical support in this
population.
Keywords: hypertrophic cardiomyopathy, left ventricular assist device, heart
failure

Introduction
Hypertrophic cardiomyopathy (HCM) is a common genetically inherited
cardiovascular disease, affecting at least 1 in 500 people world-wide (1). It is
caused by an autosomal dominant mutation in the genes that encode sarcomere
proteins or sarcomere-associated proteins (2), leading to left ventricular
hypertrophy of varying morphologies. The pathophysiology of HCM is complex
and consists of multiple interrelated abnormalities, including left ventricular outflow
obstruction, diastolic dysfunction, mitral regurgitation, arrhythmias, and myocardial
ischemia (3). The clinical diagnosis is usually made by 2D echocardiogram
imaging or cardiac MRI and it is based on the presence of a hypertrophied and
non-dilated left ventricle in the absence of another cardiac or systemic disease that
could explain the degree of hypertrophy ( ≥ 15mm wall thickness in an adult or
equivalent indexed to body surface area in a child)(4). Most patients with HCM
have normal systolic ejection fraction throughout the disease process. However,
some progress into a phase characterized by systolic dysfunction, LV dilatation,
and wall thinning, often referred to as end-stage or “burned-out” HCM (5). Dilatedhypokinetic HCM develops in 5-15% of these patients, resulting in rapid
progression of heart failure symptoms, arrhythmia and ultimately death, and is the
single most frequent indication for heart transplantation among patients with HCM
(4,6,7).
In recent years, left ventricular assist devices (LVAD) have become a standard
therapeutic option for patients with advanced heart failure (HF) due to dilated or
ischemic cardiomyopathy, with trials showing benefit in mortality compared to
medical therapy (8). Patients with HCM present unique challenges for mechanical
support with smaller LV cavities and increased wall thickness and thus are not
represented in these trials. In this study we report the characteristics, surgical and
long term outcomes of patients with burned out HCM who received LVAD therapy
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in our institution compared with those who received LVAD as treatment for dilated
or ischemic cardiomyopathy.

Methods
Between 2010 and 2014, five patients with end stage or burned-out HCM, defined
as patients with a history of HCM and systolic dysfunction with EF <50%, were
implanted with either a Heart Mate II ® (Thoratec Corp., Pleasanton, CA) or HVAD®
(HeartWare Corp., Framingham, MA) device as a bridge to transplant (BTT) or
destination therapy (DT) in our institution. We compared baseline characteristics,
surgical and long-term outcomes between these patients and non-HCM patients
who received an LVAD for end stage dilated and ischemic cardiomyopathy during
the same time frame (n=214). Baseline demographics, laboratory values,
echocardiographic and catheterization data, operative and post-operative clinical
variables were obtained via review of the medical record.

Statistical Methods
Patient characteristics were summarized by the mean ± standard deviation for
continuous variables and by frequency counts (percent) for categorical variables.
Student’s two sample t-test for independent groups and Fisher’s exact test were
used to compare between HCM and non-HCM groups for continuous and
categorical data, respectively. All non-normal and ordinal variables were
summarized by the median (1st quartile, 3rd quartile) and compared using MannWhitney U test.
Comparisons of pre and post LVAD implantation data among HCM patients were
done using paired t-tests for normally distributed continuous variables or Wilcoxon
matched-pairs signed-ranks test for non-normal and ordinal variables.
All analysis conducted in SAS v9.4. (SAS Institute Inc., Cary, NC)

Results
Baseline characteristics
There was no difference in baseline demographic characteristics (age, gender,
BMI) between the patients who received an LVAD for end stage HCM compared to
non-HCM patients (Table 1). All HCM patients were experiencing NYHA class IIIIV symptoms and were on positive ionotropic agents pre-operatively (versus only
14% of the control patients), however none received temporary mechanical
support. There was no significant difference in pre-operative hemoglobin, renal
function tests, liver function tests (LFTs), platelets or INR between the groups
(table 2).
We found that the HCM cohort had a significantly smaller LV end diastolic
diameter than the non-HCM cohort (5.2 vs 6.9cm, p=0.001) and a higher LV EF
(28% vs 18%, p=0.002) (Table 2). There were no significant differences in MR or
TR severity between groups. The HCM cohort had a higher pulmonary artery
wedge pressure than the control group (32 vs 27mmHg, p=0.006); however RA
pressure, PA systolic pressure and cardiac index values were not significantly
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different. Additionally, there was no between group difference in incidence of preoperative arrhythmia (ventricular tachycardia or atrial fibrillation) (Table 1).

Table 1. Baseline Patient characteristics
Control (n=241)

HCM (n=5)

p-value

57.19 ± 11.79

56.00 ± 13.00

0.82

195 (81%)

4 (80%)

1.00

29.07 ± 5.85

26.00 ± 3.32

0.24

History of VT
Yes

77 (47%)

1 (20%)

0.37

History of A Fib
Yes

113 (47%)

4 (80%)

0.19

Pre-op vasopressor
Yes

33 (14%)

5 (100%)

<0.001

Pre-op temporary MCS*
Yes

65 (27%)

0 (0%)

0.33

LVAD type
Heartmate II

208 (86%)

4 (80%)

HVAD

33 (14%)

1 (20%)

Age
Gender
Male
BMI

0.53

Table 1: All values reposted as n (%), mean ± SD, or median (25%
percentile, 75% percentile).
A fib = atrial fibrillation; BMI = Body mass index; VT = ventricular
tachycardia;
*temporary mechanical circulatory support = impella, balloon pump, or
ECMO
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Table 2: Baseline Laboratory and hemodynamic characteristics
Pre-VAD

Control (n=241)

HCM (n=5)

p-value

Hb (g/dL)

10.98 ± 1.73

11.48 ± 1.81

0.52

BUN (mg/dL)

36 ± 20.46

41.60 ± 9.07

0.55

Creatinine (mg/dL)

1.58 ± 0.81

1.96 ± 0.64

0.29

Platelets (k/uL)

199.29 ± 85.2

150.2 ± 50.51

0.20

Albumin (mg/dL)

3.5 (3.2, 4.0)

3.4 (3.4, 3.7)

0.74

INR

1.4 (1.3, 1.7)

1.6 (1.4, 2.2)

0.19

AST (U/L)

40.0 (27.0, 76.0)

48.0 (36.0, 65.0)

0.73

BNP (pg/dL)

1090.42 ±700.98

1366.60 ± 862.48

0.39

LVEDD (cm)

6.89 ± 1.16

5.18 ± 0.76

0.001

LV EF (%)

18.46 ± 6.72

28.00 ± 8.15

0.002

Severe MR (n, %)
Yes

51 (22%)

0 (0%)

0.59

Severe TR (n, %)
Yes

17 (7%)

0 (0%)

1.00

RA pressure (mmHg)

14.68 ± 6.67

14.60 ± 7.06

0.98

PA systolic
pressure (mmHg)

57.50 ± 13.27

58.80 ± 11.01

0.83

PVR (Wood units)

4.03 ± 2.69

4.49 ± 2.04

0.71

Wedge pressure
(mmHg)
Cardiac Index
(L/min/m2)

27.23 ± 7.78

32.00 ± 2.35

0.006

1.84 ± 0.55

1.50 ± 0.22

0.17

Table 2: All values reported as n (%), mean ± SD, or median (25% percentile,
75% percentile). Hb = Hemoglobin; LVEDD = Left ventricular end diastolic
diameter; LVEF = Left ventricular ejection fraction; MR= mitral regurgitation;
TR=tricuspid regurgitation; RA= right atrium; PVR= pulmonary vascular resistance
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Operative and post-operative outcomes
80% (n=4) of the HCM patients received a Heart Mate II ® and 20% an HVAD®.
This was similar to the control group (85% Heart Mate II ® and 15% HVAD®) (table
1). 80% of the HCM were implanted as bridge to transplant (BTT), with only one
implantation as destination therapy (DT). The median post-operative length of stay
was similar between groups at less than 30 days for both. Median duration of
LVAD support was also similar at roughly 14 months for both groups. There was
no difference in post-operative complications including bleeding, stroke, and
hemolysis between groups. One-year mortality for the HCM patients was zero
(Table 3).
Table 3: Post-VAD Outcomes
Post-VAD

Control (n=241)

HCM (n=5)

p-value

19 (8%)

0 (0%)

1.00

Peri-op pRBCs

7.0 (4.0, 14.0)

2.0 (0.0, 4.0)

0.007

LOS* (days)

29 (21.0, 43.0)

21.0 (14.0, 33.0)

0.37

Time to
Rehospitalization
(days)

39 (15.0, 99.0)

28 (24.0, 280.0)

0.35

LOS > 30 days
Yes

106 (44%)

1 (20%

0.37

Rehospitalization
(1yr) Yes

154 (72%)

5 (100%)

0.33

Hemolysis (1yr) Yes

30 (12%)

0 (0%)

1.00

GI bleed (1yr) Yes

71 (29%)

1 (20%)

1.00

Stroke (1yr) Yes

27 (11%)

0 (0%)

1.00

Death (1yr) Yes

68 (28%)

0 (0%)

1.00

13.7 (3.8, 25.4)

14 (11.0, 16.0)

0.99

RVAD need (n, %)
Yes

Implant to death or
transplant (months)

Table 3: All values reposted as n (%), mean ± SD, or median (25% percentile,
75% percentile).
pRBC = packed red blood cells; GI = gastrointestinal, LOS=length of stay
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In the patients with HCM, LVAD therapy resulted in a significant improvement in
LV end diastolic diameter (from 5.2 cm to 3.9cm), PASP (from 58.8mmHg to
30.8mmHg), and cardiac index (from 1.5 to 2.82 L/min/m2) after 3 months of
support (Table 2). 80% of the HCM patients had a baseline history of atrial
fibrillation compared to 47% in the control group, and all of them experienced postoperative atrial fibrillation (Table 4). The only HCM patient with a history of preoperative VT experienced post-operative VT. The HCM cohort received a
combined average of 2.2 units of RBCs post-operatively (Table 3). None of the
HCM patients required post-operative temporary mechanical support (Extra
Corporeal Membrane Oxygenation, Impella, Intraortic Balloon Pump or Right
Ventricular Assist Device). The HCM patients required between 5 and 7 days of
inotropic support post-operatively, without echo evidence of post-operative right
ventricular failure or dysfunction.

Table 4: Pre and post VAD comparisons among HCM patients
Variable
Cardiac Index (L/min/m2)
RV dysfunction
(1=mild, 2=moderate)

Pre
(N=5)
1.50 ± 0.22
1.0 (1.0, 2.0)

Post
(N=5)

P-value

2.82 ± 0.57

0.005

0.0 (0.0, 1.0)

0.13

58.80 ± 11.01

30.80 ± 7.05

<0.001

LVEDD (cm)

5.18 ± 0.76

3.96 ± 0.49

0.020

LVESD (cm)

4.23 ± 0.71

3.08 ± 0.77

0.002

PA systolic pressure
(mmHg)

Mitral regurgitation
(1=mild, 2=moderate)

1.0 (1.0, 2.0)

0.0 (0.0, 0.0)

0.06

Table 4: All values reposted as n (%), mean ± SD, or median (25% percentile,
75% percentile). RV=right ventricle; PA=pulmonary artery; LVESD=left
ventricle end systolic dimension
Overall, there was no increased incidence of post-operative arrhythmias, right
ventricular dysfunction, dialysis, bleeding or CVA in the HCM cohort. All 4 BTT
HCM patients were successfully transplanted, with one of them receiving a heartkidney transplant.

Discussion
In this small case series, LVAD was employed in 5 HCM patients with clinical
success. Additionally, all four BTT HCM patients were successfully supported to
orthotopic heart transplant. Our report adds to a small body of literature
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demonstrating that, despite difficulties related to the nature of the disease, LVAD
can be used successfully in selected HCM patients.
This is one few, and largest, series to report that LVAD therapy can be used in
patients with end stage HCM, without added morbidity and mortality. The first
reported case series included four patients with dilated HCM implanted with axial
continuous flow devices, and showed LVAD therapy did not result in increased
morbidity or mortality (9). Another case series with three patients showed that
patients with HCM benefited from LVAD therapy with centrifugal continuous flow
devices in the short to medium term (10). Our findings are in agreement with the
previous reports and add evidence to support use of this technology when and if
necessary in this population.
Patients with end stage HCM represent a different cohort than those with dilated
and ischemic cardiomyopathy. As mentioned, the pathophysiology of HCM is
complex and is characterized by left ventricular outflow obstruction, diastolic
dysfunction, mitral regurgitation, increased burden of arrhythmias, and myocardial
ischemia. The ventricular geometry is also different, with small cavities, thicker
walls, and redundant mitral valve leaflets, which is a potential technical concern for
LVAD placement and function. They are at a high risk of sudden death due to
heart failure and arrhythmias; a risk that increases markedly with increase in
NYHA class (4). Medical therapy for these patients remains limited due to different
pathophysiology than those with dilated or ischemic cardiac disease. Afterload
reduction and diuresis is often poorly tolerated, resulting in increased outflow
obstruction, hypotension and renal injury, while ionotropic agents can increase the
risk of arrhythmias (11). LVAD therapy has been shown to improve outcomes in
patients with advanced dilated or ischemic cardiomyopathy who are failing
maximal medical therapy (12, 13). However patients with HCM have not been
represented in the LVAD trials. There is concern for increased suck down events
and arrhythmias due to smaller LV cavity size in these patients, as well as RV
dysfunction post LVAD implantation.
Progression to end stage dilated-hypokinetic stage occurs in ~10-15% of patients
with HCM (14). Once LV dilatation is established, the evolution toward severe
heart failure and death is often rapid, with reported refractoriness to medical
therapy and more severe symptoms than those with idiopathic dilated CM, despite
overall better EF (6). Duration from onset of end-stage HCM to death or
transplantation was reported to be only ~2.7 years in one report by Harris, et al.
(15). This is consistent with our data, showing that all of the HCM patients were
experiencing NYHA class IV symptoms requiring ionotropic support prior to LVAD
implantations, despite a significantly higher EF than the control group. A
combination of altered ventricular geometry with smaller cavity size, resulting in
similar or even reduced effective stroke volume despite higher EF, as well as
severe combined diastolic and systolic dysfunction in HCM likely contribute to this
discrepancy.
Cardiac transplantation remains the optimal treatment option for end-stage HCM
patients. However, the numbers of patients needing transplantation and, as a
result, the transplant wait times are increasing. Consequently, end-stage HCM
patients are at risk of progressing to irreversible pulmonary hypertension,
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refractory heart failure and ultimately death without further advanced HF therapy
options. The use of LVAD therapy has markedly increased over the recent years,
with overall transplant numbers remaining the same. As a result, the proportion of
patients transplanted after VAD therapy continues to increase. In the last year,
approximately 90% of patients undergoing heart transplant in our center had
previously received an LVAD. Given high morbidity and mortality associated with
end-stage HCM and the scarcity of the ideal therapy, heart transplantation, LVAD
placement is a reasonable next step. This is the largest case series reporting that
selected patients with end stage HCM can benefit from LVAD therapy without
increased morbidity and mortality, similarly to those with dilated and ischemic
cardiomyopathy. LVAD therapy appears to be a viable therapy for selected
patients with end stage hypertrophic cardiomyopathy awaiting cardiac
transplantation.
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